BTK Kinase Activity Assay Kit: A Core Tool for Targeted Therapy Research in B-Cell Lymphoma

Author: Senior Product Manager of UA Views：13

This article systematically elucidates the central role of Bruton's tyrosine kinase (BTK) in BCR signaling transduction and its driving effect in the development of B-cell lymphoma, analyzes the differential mechanisms and target characteristics of different generations of BTK inhibitors, and explores the application strategies of the BTK kinase activity detection kit in BTK inhibitor screening, selectivity evaluation, and resistance mechanism research.

Recent Advances
Product Information

Recent Advances

BTK Kinase Activity Assay Kit: A Core Tool for Targeted Therapy Research in B-Cell Lymphoma

Summary

This article systematically elaborates on the technical principles and application systems of the BTK kinase activity assay kit, highlighting the central role of Bruton's tyrosine kinase (BTK) in BCR signaling transduction and its driving effect in the pathogenesis of B-cell lymphoma. It analyzes the differential mechanisms and target characteristics of different generations of BTK inhibitors and explores the application strategies of the assay kit in BTK inhibitor screening, selectivity evaluation, and resistance mechanism research.

I. Molecular Structure of BTK and Its Central Role in the BCR Signaling Pathway

Bruton's tyrosine kinase (BTK) is a protein composed of 659 amino acids and belongs to the Tec family of non-receptor tyrosine kinases. BTK is widely expressed in all hematopoietic cells except T cells and plasma cells. BTK contains five domains: PH domain, TH domain, SH3 domain, SH2 domain, and SH1/TK catalytic domain, which recognize and bind various signaling molecules. The B-cell antigen receptor (BCR) is one of the specific markers of B cells and is a complex composed of membrane immunoglobulin and Igα (CD79a)/Igβ (CD79b). The BCR signaling pathway participates in normal B-cell growth, development, and differentiation, with BTK being a key kinase in this pathway, transmitting signals received by BCR and regulating B-cell proliferation and survival.

Upon binding with antigens, the BCR signaling pathway is activated. First, BCR aggregation is induced due to antigen multivalency, leading to phosphorylation of ITAM residues on the cytoplasmic tails of CD79A and CD79B, forming a signaling complex. Second, aggregated BCR triggers phosphorylation of Src family molecules (LYN, SYK, FYN, BLK, etc.). Subsequently, Src family molecules phosphorylate the Tyr551 site in the catalytic domain of BTK, activating the catalytic domain and triggering autophosphorylation of the Tyr223 site in the SH3 domain. Ultimately, dual-site phosphorylation is the activated form of BTK. BTK participates in the transmission and amplification of various cellular signals in B lymphocytes, activating pathways such as MAPK, NF-κB, and transcription factors (NFAT), thereby regulating gene expression and inhibiting B-cell apoptosis. In summary, normal BTK expression is crucial for B-cell maturation, survival, differentiation, apoptosis, and migration.

II. Abnormal BCR Signaling Pathway and the Pathogenesis of B-Cell Lymphoma

The BCR signaling pathway is a key driver of growth and dissemination in various B-cell lymphomas. Most B-cell lymphomas express membrane immunoglobulin and BCR polymers. In the BCR signaling pathway, certain enzymes can cause chromosomal translocations, altering immunoglobulin gene loci and forming oncogenes. Meanwhile, BCR binding with antigens activates the BCR signaling pathway, promoting tumor cell growth and survival.

The BCR signaling pathway mediates the pathogenesis of chronic lymphocytic leukemia (CLL). Studies have found significant spontaneous BCR signal transduction in CLL patients, as well as upregulated expression of BCR signaling-related genes in CLL cells. Overactivation of the BCR pathway induces the production of pro-survival factors, including anti-apoptotic BCL-2 family proteins and myeloid leukemia cell differentiation protein (Mcl-1), thereby inhibiting tumor cell apoptosis. Research on mantle cell lymphoma (MCL) has revealed upregulated phosphorylation levels of BCR signaling-related molecules, indicating that excessive activation of the BCR pathway is one of the pathogenic mechanisms of MCL. In MCL, BTK is highly expressed, and the Tyr223 site in the SH3 domain is abnormally phosphorylated, with some patients also exhibiting constitutive phosphorylation of other domains. These findings establish the molecular basis of BTK as a therapeutic target for B-cell lymphoma.

III. Differential Mechanisms and Target Characteristics of BTK Inhibitors

BTK activates downstream B-cell survival pathways, such as MAPK and NF-κB, through Src family molecules, which play a crucial role in BCR signal transduction. When BTK is inhibited, B-cell apoptosis significantly increases, correlating with reduced activity of BCR-mediated anti-apoptotic protein Bcl-xL. Additionally, BTK-deficient B cells struggle to transition from the G1 phase to the S phase of the cell cycle, affecting B-cell proliferation.

BTK inhibitors (BTKis) are classified into three generations. Both first- and second-generation BTKis irreversibly and covalently bind to the Cys481 site in the BTK catalytic domain, preventing the catalytic domain from functioning and inhibiting autophosphorylation of the Tyr223 site in the SH3 domain, thereby suppressing BTK activity. Due to differences in chemical structure design, first- and second-generation BTKis exhibit varying specificity for BTK Cys481, with second-generation BTKis showing higher specificity. Third-generation BTKis inhibit the BTK pathway by forming hydrogen bonds and non-covalently binding to BTK, thereby suppressing its activity.

Although first-generation BTKis demonstrate good clinical efficacy, their specificity is insufficient, leading to more common off-target effects. Kinases containing the Cys481 cysteine residue, including TEC family kinases (e.g., ITK), epidermal growth factor receptor (EGFR), and Janus kinase 3 (JAK3), are off-target inhibited by first-generation BTKis, often resulting in side effects and toxic reactions across multiple organs and systems. Second-generation BTKis enhance binding efficacy and selectivity for BTK, showing significant therapeutic effects without inhibiting pathways such as EGFR and ITK, thereby reducing off-target effects and adverse reactions. Third-generation BTKis reversibly bind to BTK by forming hydrogen bonds with other sites (e.g., K430, M477), inhibiting BTK activity.

IV. Application Strategies of BTK Kinase Activity Assay Kit in Drug Discovery

The BTK kinase activity assay kit is integral to multiple key stages of BTK-targeted drug discovery. In compound screening, the kit can be used to establish high-throughput screening platforms, identifying lead compounds with BTK inhibitory activity from large compound libraries. In generational selectivity evaluation, parallel detection of compound inhibitory activity against BTK wild-type and Cys481 mutants can assess covalent binding properties and the ability to overcome resistance mutations. In off-target effect evaluation, the kit can detect compound selectivity for kinases containing Cys481, such as EGFR, ITK, and JAK3, reducing potential side effect risks. In mechanism-of-action studies, varying ATP concentrations can determine inhibitor competition types, distinguishing between covalent irreversible inhibitors and reversible non-covalent inhibitors.

In experimental design, the following key factors should be considered. Substrate and ATP concentrations should be optimized to ensure the detection system operates within the optimal linear range. Reaction time and temperature should be standardized based on BTK kinase characteristics. For covalent inhibitors, pre-incubation time's impact on inhibition efficiency should be considered. Positive and negative controls are recommended to validate the experimental system's effectiveness.

V. Conclusion

In practical applications of BTK kinase activity assays, high-quality detection reagents are crucial for ensuring data reliability and experimental reproducibility. To meet the demands of BTK kinase activity detection, UniOne provides the UniOne® TR-FRET KinActive-BTK Kit. This product, based on TR-FRET detection technology, offers the following core features: leveraging the long fluorescence lifetime of lanthanide donors to effectively reduce background interference through delayed detection; homogeneous operation mode requiring no washing or separation steps, compatible with high-throughput formats in 96- and 384-well plates; excellent signal stability, supporting batch processing and flexible time windows; suitable for kinase activity detection of BTK wild-type and Cys481 mutants. The kit is applicable to scenarios such as BTK inhibitor screening and structure-activity relationship analysis, generational selectivity evaluation, and BCR signaling pathway mechanism research.

As a core tool for targeted therapy research in B-cell lymphoma, the BTK kinase activity assay kit, with its TR-FRET-based homogeneous detection method, provides a systematic solution for the discovery and optimization of BTK inhibitors. From BTK wild-type to Cys481 resistance mutants, from compound screening to off-target effect evaluation, the BTK kinase activity assay kit continues to play an irreplaceable supporting role. The UniOne® TR-FRET KinActive-BTK Kit offers reliable tool support for BTK kinase activity detection, driving innovation in the field of targeted therapy for B-cell lymphoma.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next